The TCR-based therapy market is projected to grow at an annualized rate of 51%, claims Roots AnalysisGiven the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications Roots Analysis has announced the addition of “Global TCR-based Therapy Market (2nd Edition), 2022-2035” report to its list of offerings.
Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Growing burden and unaddressed complex treatment needs of cancer patients have paved the way for more effective, safe and versatile alternatives, such as TCR therapies. Driven by Kimmtrak® approval, promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is anticipated to witness significant growth in the mid to long-term

Key Market Insights
Over 190 TCR-based therapies are currently approved / under development
Close to 45% of the aforementioned candidates are being evaluated in clinical trials (phase I and above), while 30% of them are in preclinical stage of development. More than 90% of the therapy candidates, which are being developed to target a range of disease indications, are autologous in nature. Further, NY-ESO-1 and MAGE have emerged as the most popular target antigens.

More than 7,000 patients have been enrolled in nearly 110 clinical trials, worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the last five years. Of the total number of trials, close to 65% are active and still recruiting patients, while close to 26% have already been completed.

Partnership activity within this domain has grown at a CAGR of 27%, between 2015 and 2021
More than 70 agreements have been inked in the last 5 years. Majority of partnership deals signed within this domain were R&D agreements (26%), licensing agreements (21%), and product development and commercialization agreements (16%).

Over 11.2 USD billion has been invested by both private and public investors in this domain, since 2007
Specifically, in 2020 and 2021, industry players raised over USD 2.7 billion. In addition, majority (39%) of the companies primarily received funding through venture capital rounds. Further, around 70% of the total funding instances were reported by players headquartered in the US.

More than 70 patents have been filed / published related to the TCR-based therapies
Close to 85% of the filed / published patents were patent applications, while around 15% were granted patents and others. Of the total granted applications, close to 45% were filed in North America and Europe.

The market is anticipated to grow at a CAGR of 51%, during the period 2022-2035
In 2035, close to 60% of the market revenues are expected to be generated from sales of therapeutics intended for Nasopharyngeal Carcinoma and Multiple Myeloma. Further, therapies targeting for NY-ESO-1 are expected to occupy a larger share (~50%) of the overall market in 2035.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/tcr-based-th

Key Questions Answered
 What is the growth rate of TCR-based therapy market?
 Which region has the highest growth rate in the TCR-based Therapies market?
 Who are the leading industry and non-industry players in this market?
 How many players are developing TCR-based Therapies?
 Which target indication covers the largest TCR-based therapy market share?
 What is the partnership and collaboration trend in the TCR-based therapy domain?
 What is the current IP landscape of TCR-based therapies market?

The financial opportunity within the TCR-based therapies market has been analyzed across the following segments:
 Target Indication(s)
 Nasopharyngeal Carcinoma
 Multiple Myeloma
 Head and Neck Carcinoma
 Sarcoma, Melanoma
 Acute Myeloid Leukemia
 Lung Cancer
 Ovarian Cancer
 Merkel Cell Cancer

 Target Antigen
 NY-ESO-1
 EBV
 gp100
 Others

 Key Geographical Regions
 North America
 Europe
 Asia Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, T-cell immunotherapies are expected to be the next big step in cancer immunotherapy. The report includes detailed transcripts of discussions held with the following experts:
 Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
 Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
 Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
 Miguel Forte (Former Chief Operating Officer, TxCell)

The report includes brief profiles of key players (listed below); each profile features an overview of the company, details related to its financial information (if available), details about TCR-based product(s), such as information on type of therapy and current development status, information on technology portfolio (if available), recent developments related to TCR-based therapies and manufacturing capabilities of the players.
 Adaptimmune Therapeutics
 Alaunos Therapeutics
 Bristol Myers Squibb
 Cellular Biomedicine Group
 Gilead Sciences
 GlaxoSmithKline
 Immatics
 Immunocore
 Lion TCR
 Takara Bio
 Zelluna Immunotherapy

For additional details, please visit https://www.rootsanalysis.com/....reports/tcr-based-th or email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (6th Edition), 2022- 2035
2. mRNA Therapeutics and mRNA Vaccines Market (2nd Edition), 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.


Contact:
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - TCR Therapies Market | Industry Analysis | Market Size | 2035

TCR therapies market, driven by over 190 TCR therapies in pipeline and USD 11 billion investment, is anticipated to grow at over 50% CAGR in the coming decade

The global cell cytometry market is anticipated to grow at a CAGR of ~10%, till 2035, claims Roots Analysis

In order to accommodate the growing demand for higher accuracy, greater resolution and improved sensitivity in analytical processes, various industry stakeholders are engaged in the development of novel cytometry platforms with advanced features.Roots Analysis has announced the addition of “Global Cell Cytometry Market: Focus on High Throughput Flow Cytometry and Image Cytometry, 2022-2035” report to its list of offerings.

Novel cell cytometry platforms has emerged to be the crucial analytical and visualization tools with applications across various areas, such as immunology, molecular biology, cancer biology and infectious disease monitoring. As a result, developers are currently engaged in the development of technologically advanced cell cytometry platforms that offer better throughput and accuracy.

Key Market Insights

Currently, more than 180 high throughput flow cytometry and image cytometry platforms are available in the market
Majority (92%) of the high throughput flow cytometers are cell analyzers. Of these, ~40% of the devices operate at a throughput rate of 4 to 15 wells per minute. Similarly, majority (~50%) of the image cytometers can operate as both cell analyzers and cell sorters. Of these, 90% of the devices offer qualitative analysis.

Presently, more than 25 developers are engaged in the development of cell cytometers, globally
Notably, around 40% of the developers that offer high throughput flow cytometers are very large players (having more than 5,000 employees). In addition, 45% of the image cytometer developers were established post 2000. Of these, 75% of the players are headquartered in North America.

Partnership activity in the global cell cytometry market has increased at steady rate, between 2017 and 2021
The maximum number of partnerships were established in 2021. Majority of the instances captured in the report were acquisitions and distribution agreements (25%, each). In addition, 75% of the deals have been inked by players headquartered in North America.

180+ USD million has been invested by various private and public investors in this domain, since 2017
Specifically, in 2020, the players raised over USD 125 million. It is worth noting that, majority (around 75%) of the investments were made in the form of venture capital rounds. Interestingly, around 45%of the funding instances were reported by mid-sized players (51 to 500 employees).

Close to 35 global events related to cell cytometry have been organized, since 2018
Majority of the global events related to cell cytometry include webinars (over 40%) and conferences (~35%). It is worth highlighting that the main agenda of these events was to discuss the advantages of novel cell cytometers and their potential applications.

~500 patents have been granted / filed for cell cytometers, since 2020
70% of these were patent applications; Of these, close to 50% of the patents have been filed in 2021. It is worth noting that 45% of the patents related to cell cytometry were filed / granted in China alone, followed by US (~30%).

The overall market is anticipated to grow at a CAGR of ~10%, during the period 2022-2035
North America and Europe are anticipated to capture around 35% of the market share, by 2035. In terms of types of cytometers, the image cytometers are expected to occupy a larger share (more than 55%) of the overall market in 2035.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/....reports/cell-cytomet


Key Questions Answered
 Who are the leading players engaged in the development of high throughput flow cytometers and image cytometers?
 Which are the popular types of cytometers available in the market?
 Which partnership models are commonly adopted by stakeholders engaged in this industry?
 What are the investment trends and who are the key investors actively engaged in the development and commercialization of cell cytometers?
 What are the key agenda items being discussed in various global events / conferences held related to cell cytometry platforms?
 How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the cell cytometry market has been analyzed across the following segments:
 Type of Cytometer
 High Throughput Flow Cytometer
 Image Cytometer
 Company Size
 Very Small
 Small
 Mid-sized
 Large
 Very Large
 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Rest of the World

The research also includes detailed profiles of key players (listed below) engaged in the cell cytometry market; each profile features an overview of the company, recent developments, and an informed future outlook.

 Agilent
 Beckman Coulter Life Sciences
 Becton Dickinson
 Bio-Rad
 Chemotec
 Milkotronic
 Nexcelom Bioscinces
 Sartorius
 Sony Biotechnology
 Thermo Fischer Scientific
 Union Biometrica

For additional details, please visit https://www.rootsanalysis.com/....reports/cell-cytomet or email sales@rootsanalysis.com


You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035
About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Global Cell Cytometry Market | Industry Analysis | Market Size | 2035

Global cell cytometry market, driven by over 180 products in the market, is anticipated to grow at around 10% annually over the coming decade

https://sattakingg.in/satta-king-gali-record.php
https://sattakingm.in
Satta king is a popular game that is played on daily basis. #satta A lot of #sattaking bet on the different games in the satta king. The results of these games are posted online. The company that runs these games usually fixes the timing of the results so that you https://sattakingm.in don't have to wait for hours to get the result. But, if you want to get the result faster, you can find a website https://sattakingg.in/
on the internet that will give you the result at once.

 

sattakingg.in

Satta king gali record chart 2022

Satta king, Sattaking, Satta king 2022, Satta king up, Satta result, Satta king result, Satta king online, Gali result, Desawar result, Satta king chart, Satta king live, Gali satta, Deshawar live result, Gali live result, Satta matka, Satta matka ki

Satta Matka Online Game | Poker player
https://sattakingm.in/
https://sattakingg.in/

Satta Matka is a gambling game that originated in India. It is played between two or four people. Each player selects three numbers from a pack of playing cards. The player who predicts the correct number wins a prize. The winning number is announced at an allotted time.

The dental 3D printing market is anticipated to grow at a CAGR of 15.1% during the period 2023-2035, claims Roots AnalysisThe growing burden of dental diseases and the challenges associated with the conventional dental product manufacturing methods has significantly increased the adoption of 3D printing in the dental industryRoots Analysis has announced the addition of “Dental 3D Printing Market, 2023 – 2035” report to its list of offerings.

The popularity of 3D printing technology within the dental industry can be attributed to its ability to print high quality / accurate dental products, including crowns, bridges, dentures, dental implants and surgical guides. Driven by the overall growth of the additive manufacturing (3D printing) industry, and wide adoption of 3D printers in the dental sector, the dental 3D printing market is anticipated to witness a steady growth in the foreseen future.


Key Market Insights

Currently, around 230 dental 3D printers are available for use across wide range of applications
Majority (38%) of the dental 3D printers use digital light processing (DLP) as printing technology, followed by those using stereolithography (SLA) technology (21%). Further, close to 75% of the dental 3D printers can produce crowns / bridges / dentures, followed by those manufacturing working models (61%) and surgical guides (59%). It is worth highlighting that around 55% of the dental 3D printers currently available in the market have a price range below USD 10,000.

More than 80 companies claim to offer dental 3D printers, across the world
Majority of the firms (46%) engaged in this domain are mid-sized players, followed by large (32%) and small firms (22%). It is worth highlighting that, more than 50% of the companies in this domain have been established post-2010. Further, around 85% of the dental 3D printer manufacturers are based in Asia-Pacific and Europe, followed by those headquartered in North America (16%), and within the Asia-Pacific region, China emerged as the most prominent hub, featuring the presence of maximum number of players (62%).

Partnership activity has grown at an annualized rate of over 70%, between 2018-2022
Maximum number of partnerships were established in 2021 (56) and 2022 (44), indicating the recent surge in the partnership activity in this domain. Majority of these (26%) were product integration agreements. Further, most of the intercontinental as well as intracontinental deals have been inked by the players based in North America.

500+ patents related to dental 3D printing have been granted / filed between 2019 and 2022
R&D activity related to dental 3D printing is largely concentrated in Asia-Pacific, considering the fact that 50% of the total number of patents were filed in this region. It is worth highlighting that, within the Asia-Pacific region, China emerged as the most active country with ~230 filed patents. In addition, most of the patents in this domain are patent applications (65%).

North America and Europe are anticipated to capture around 75% share of the market by 2035
In addition, the market in Asia-Pacific is likely to grow at a relatively faster pace (with CAGR of 16.3%) in the long term. Further, in 2035, based on type of printing technology, majority of the revenue share (64%) of the overall market is likely to be driven by vat polymerization technology. Further, in terms of application area, prosthodontics currently holds largest share (55%) of the market.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr

Key Questions Answered
 How is 3D printing used in the dental industry?
 How many dental 3D printers are currently available in the market?
 Which 3D printers are best for dentistry?
 What is the growth rate of the dental 3D printing market?
 Which region captures the largest share of the dental 3D printing market?
 Which printing technology is widely used in the dental 3D printers?
 Which application area currently holds the largest share in the dental 3D printing market?
 What are the partnerships and collaborations trend in the dental 3D printing domain?
 How many patents have been filed / granted related to dental 3D printing in the recent years?

The financial opportunity within the dental 3D printing market has been analyzed across the following segments:
 Type of Printing Technology
 VAT Polymerization Technology
 Powder Bed Fusion Technology
 Polyjet Technology
 Metal Extrusion Technology
 Other Technologies

 Application Area
 Prosthodontics
 Orthodontics
 Dental Implants
 Other Applications

 Type of Printing Material
 Resins
 Plastics
 Metals
 Metals
 Other Material

 Key Geographical Regions
 North America
 Europe
 Asia-Pacific
 Latin America
 Middle East and North Africa
 Rest of the World

The research also includes detailed profiles of key players (listed below) featuring a brief overview of the company, details related to dental 3D printer portfolio, recent developments, and an informed future outlook.
 3D Systems
 Asiga
 BEGO
 Carbon
 Digital Wax Systems (DWS)
 Formlabs
 Prodways
 Rapid Shape
 SprintRay
 Stratasys

For additional details, please visit
https://www.rootsanalysis.com/....reports/dental-3d-pr
or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035
2. Medical Devices Contract Research Organizations Market (3rd Edition): Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.



Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com

https://sattaking.vip

THE PHARMACEUTICAL INDUSTRY IS PRESENTLY EXPERIENCING A PROMINENT NEED FOR BIOAVAILABILITY ENHANCEMENT TECHNOLOGIES AND SERVICES
Over the last couple of decades, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. It is considered to be one of the most important pharmacokinetic properties of a drug. Bioavailability refers to the proportion of a drug that reaches systemic circulation unaltered, post dose administration. Additionally, it is a direct consequence of the absorption potential of an active pharmaceutical ingredient (API). The bioavailability of a drug is dependent on several factors, such as solubility, route of administration and metabolism of the drug post administration. The following figure provides different factors that have been reported to impact drug bioavailability either directly or indirectly. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. An increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/198/request-

 Solubility: The solubility of a substance refers to its ability to dissolve in a solvent and form a homogeneous system. Drug solubility is considered to be one of the most important factors responsible for enabling a therapeutic intervention to be efficiently distributed via systemic circulation. It is worth highlighting that a drug’s solubility is directly proportional to its bioavailability and hence, is one of the primary parameters that is modified during bioavailability enhancement
 Permeability: Permeability refers to the ability of a molecule to pass through biological membranes. Similar to solubility, drug permeability plays a key role in its absorption and systemic distribution. Membrane based efflux mechanisms and other structural barriers are the major biological elements responsible for poor permeability of drugs. Permeability of a drug is also proportional to its bioavailability; however, it is possible to improve this characteristic by modifying the physiochemical properties of the drug to render them more suitable for absorption across different types of biological membranes.
 Molecule Size: Rate of absorption increases inversely with the size of a drug molecule. However, several studies have demonstrated that, absorption mechanisms vary significantly for different sizes of molecules. For instance, larger molecules get absorbed either by endocytosis or facilitated diffusion, whereas smaller molecules are absorbed via aqueous diffusion or through lipid channels.
 Degree of Ionization: Degree of ionization has a direct impact on drug absorption. Higher degree of ionization of a drug molecule results in poor solubility. As a general rule, basic drugs get ionized in acidic medium and are therefore, poorly soluble in acidic medium. The same rule applies to acidic drugs in basic medium.
 Formulation: The formulation process involves the addition of certain excipients, which are inactive substances that augment the properties of the drugs. Despite being inactive, these substances can influence drug bioavailability.
 Concentration: According to Fick’s law of diffusion, higher drug concentration in a tissue microenvironment, leads to higher flux through the membrane, resulting in a high rate of absorption.
 Dosage Forms: Drugs can be administered into the body via a number of routes, such as oral, transdermal, ocular and intramuscular. However, it is important to note that the mode of administration plays a very significant role in drug bioavailability. Several studies have demonstrated that only intravenous injections offer 100% drug availability in systemic circulation compared to any other route.
 Physical Forms: The physical form of the drug (solid, liquid or inhalable powder) also affects its rate of absorption. It is worth highlighting that drugs get more absorbed in gaseous form followed by liquid and solid form respectively.

 Chemical Nature: The chemical make-up of a drug is also an important determinant of its absorption potential and bioavailability. It has been observed that inorganic salts are more readily absorbed than organic compounds, when administered via the oral route.

Further, given the rapid increase in the number of NCEs with low solubility and considering that this trend persists in the future as well, there is likely to be a surge in the demand for technologies that facilitate bioavailability enhancement. There are a number of technologies which are already available for improving drug bioavailability. Broadly these technologies can be distributed across three main categories, namely physical, chemical and biological approaches. However, as pharmacological interventions gradually become more complex and novel drug classes are introduced, further innovation may be required in the development of better bioavailability enhancement techniques / methods.

For additional details, please visit
https://www.rootsanalysis.com/....reports/view_documen or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. RNAi Market: Therapeutics and Technologies (Focus on siRNA, miRNA, shRNA and DNA) (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
2. Global Therapeutic Vaccines Market: Industry Trends and Global Forecasts, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

 

www.rootsanalysis.com

Request Sample - Bioavailability Enhancement Technologies and Services | Market Size | 2035

The space of bioavailability enhancement technologies and services, driven by the increase in number of BCS II and BCS IV molecules in early phases of development, is likely to grow at CAGR of ~11%, till 2035

Patient Recruitment and Retention Service ProvidersClinical trials form an essential part of the overall drug development process, evaluating the safety and efficacy of a drug candidate. Studies suggest that around 40% of the total investment made for the development of a drug candidate is dedicated to clinical trials. However, the conduct of such trials is often fraught with challenges, including scientific and operational complexity, concerns associated with recruitment and retention of suitable patients, issues related to data handling and increasingly stringent regulatory guidelines. Further, owing to the inherent complexity of the overall process and involvement of several different stakeholders, these trials are prone to delays. It is worth mentioning that around 80% of the clinical trials are delayed due to insufficient patient recruitment.

To request a sample copy / brochure of this report, please visit
https://www.rootsanalysis.com/....reports/245/request-

Further, retaining patients is also a major concern in pharmaceutical research and development; 15% to 40% of the enrolled patients drop out before the studies are completed, significantly impacting product approvals / launch timelines. Therefore, patient outreach, recruitment and retention strategies have evolved significantly, especially with the availability of a variety of digital data generation, management and marketing solutions. In fact, a number of modern technology-enabled offerings are now available to support various aspects of clinical research and patient recruitment.

Several players do not have dedicated patient enrolment teams and lack the necessary capabilities / expertise to successfully recruit desired number of patients in clinical trials. In some cases, the clinical studies are too large or geographically broad to be managed by internal staff. Further, the stringent ethical and regulatory guidelines associated with patient enrollment in trials impose a significant burden on drug developers. As a result, outsourcing has become a popular operating model with regards to patient retention. The advantages of engaging contract service providers are numerous and enable sponsors to meet their clinical research timelines and thereby, launch respective offerings as planned. Presently, more than 155 companies have the required capabilities to offer patient recruitment services and patient retention services across different geographical locations.

For additional details, please visit link https://www.rootsanalysis.com/....reports/view_documen

You may also be interested in the following titles:
1. Gene Therapy Market: Industry Trends and Global Forecast, 2022-2035
2. 3D Cell Culture Market (4th Edition): Industry Trends and Global Forecast, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
ben.johnson@rootsanalysis.com

Driven by the growing demand for medical devices, novel coatings providing unique features are being introduced in the marketOver the past 50 years, the medical device industry has seen several notable developments. In fact, the use of biomedical devices, such as medical implants, surgical instruments, and prostheses has increased substantially over the time. Cardioverter defibrillators, prosthetic hips and knees, contact lenses, and cardiac pacemakers are some of the most commonly implanted medical devices, while fixation devices and artificial joints account for about 44% of all medical devices. Despite significant advancements in the design and implantation of medical devices, a number of challenges still persist. Patients, particularly those who are immunocompromised, are at high risk of healthcare-associated infections (HAIs) due to the in-dwelling nature of implanted devices and surgical tools. The risk of infections along with limitations including, implant rejection, osseointegration, degradation and wear, loom over the prosthetic integration. Coatings on biomedical implants can affect this biological interaction between the implant and host, mitigate joint wear, and combine the properties of several materials to enhance device performance as well as reduce the risks associated with invasive medical devices. Medical device coatings also endow properties like lubrication, anti-fouling nature, as well as enhanced durability to the surface of the device. Driven by the surge in demand for various types of medical devices and the need for a wide array of coatings for these devices, the medical device coatings market is anticipated to witness a steady growth in the coming decade.

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/....reports/medical-devi

One of the key challenges associated with in-dwelling medical devices lies in the fact that they are in constant association with the bodily fluids, therefore, interacting with a wide variety of proteins and other biomolecules. This results in denaturization of the biomaterials over time, reducing the overall functional life of the device. As a counter to this problem, surface modification can be utilized. Generally, protein adsorption and biological interactions are significantly impacted by the biomaterial surface modifications, such as modifying the chemistry of polymers, coefficient of friction, domain layout, and shape. Surface modifications, such as plasma spraying, vacuum depositions, etching, and electro-depositions are some of the most frequently procedures to achieve the necessary alterations on medical device surfaces.

Various medical devices are associated with the risk of infections, cytotoxicity, thrombogenesis, and immune rejection, which has garnered the attention towards appropriate selection of suitable biomaterials and strategies for modifying the medical devices surface. One of the key developments in the area has been made in creating non-fouling / antibacterial surfaces. A breakthrough in this field has been witnessed in graphene coatings developed to elicit antimicrobial properties. As an alternative to the use of silver nanoparticles earlier, the use of graphene in healthcare applications has a promising future, given the fact that graphene would provide more secure antibacterial properties than metal nanoparticles along with cost efficiency. The detailed competitiveness analysis of various medical device coating providers identified during our research, which are based in North America, Europe, and Asia.

Integration of new technologies like advanced laser processing, machine learning, and automation using Artificial Intelligence (AI) also drives the field towards more precise and reproducible coating / surface treatment applications, which can revolutionize the biomedical devices industry.

For additional details, please visit https://www.rootsanalysis.com/....reports/medical-devi or email sales@rootsanalysis.com

You may also be interested in the following titles:
1. Targeted protein degradation market, 2022-2035
2. Single-Use Upstream Bioprocessing Technology / Equipment Market, 2022-2035

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnson@rootsanalysis.com